GLRA
TCRT icon

Gerald L. Ray & Associates’s Alaunos Therapeutics TCRT Stock Holding History

Gerald L. Ray & Associates’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-146
Closed -$136K – 333
2017
Q2 		$136K Sell
146
-46
-24% -$45.1K 0.02% 315
2017
Q1 		$183K Sell
192
-1
-0.5% -$931 0.03% 310
2016
Q4 		$155K Sell
193
-2
-1% -$1.8K 0.02% 305
2016
Q3 		$164K Buy
195
+28
+17% +$22.5K 0.02% 312
2016
Q2 		$137K Sell
167
-3
-2% -$3.27K 0.02% 298
2016
Q1 		$189K Buy
170
+21
+14% +$21.5K 0.03% 289
2015
Q4 		$186K Buy
149
+2
+1% +$3.31K 0.03% 295
2015
Q3 		$198K Buy
147
+49
+50% +$80.9K 0.03% 290
2015
Q2 		$176K Buy
+98
New +$152K 0.03% 303

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gerald L. Ray & Associates's TCRT Position: Q3 2017 in Review

Gerald L. Ray & Associates sold out of Alaunos Therapeutics (TCRT) in Q3 2017, closing a stake of 146 shares — an estimated $136K sold.

Gerald L. Ray & Associates first reported a position in TCRT in Q2 2015 and held it in 9 quarters. The position peaked at $198K in Q3 2015. 122 funds tracked by Wall St. Rank hold TCRT as of Q3 2017.

  • Gerald L. Ray & Associates reported no remaining Alaunos Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Gerald L. Ray & Associates sold 146 Alaunos Therapeutics shares in Q3 2017, an estimated $136K.
  • Gerald L. Ray & Associates first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 9 quarters.
  • Gerald L. Ray & Associates's Alaunos Therapeutics position peaked at $198K in Q3 2015.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2017.

Based on Gerald L. Ray & Associates's 13F filing for Q3 2017, filed 31 Oct 2017.